Literature DB >> 16419055

Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene.

Laura J C M van Zutven1, Emine Onen, Sandra C J M Velthuizen, Ellen van Drunen, Anne R M von Bergh, Marry M van den Heuvel-Eibrink, Angelo Veronese, Cristina Mecucci, Massimo Negrini, Georgine E de Greef, H Berna Beverloo.   

Abstract

Chromosome rearrangements are found in many acute leukemias. As a result, genes at the breakpoints can be disrupted, forming fusion genes. One of the genes involved in several chromosome aberrations in hematological malignancies is NUP98 (11p15). As NUP98 is close to the 11p telomere, small translocations might easily be missed. Using a NUP98-specific split-signal fluorescence in situ hybridization (FISH) probe combination, we analyzed 84 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia, or myelodysplastic syndrome with either normal karyotypes or 11p abnormalities to investigate whether there are unidentified 11p15 rearrangements. Neither NUP98 translocations nor deletions were identified in cases with normal karyotypes, indicating these aberrations may be very rare in this group. However, NUP98 deletions were observed in four cases with unbalanced 11p aberrations, indicating that the breakpoint is centromeric of NUP98. Rearrangements of NUP98 were identified in two patients, both showing 11p abnormalities in the diagnostic karyotype: a t(4;11)(q1?3;p15) with expression of the NUP98-RAP1GDS1 fusion product detected in a 60-year-old woman with AML-M0, and an add(11)(p15) with a der(21)t(11;21)(p15;p13) observed cytogenetically in a 1-year-old boy with AML-M7. JARID1A was identified as the fusion partner of NUP98 using 3' RACE, RT-PCR, and FISH. JARID1A, at 12p13, codes for retinoblastoma binding protein 2, a protein implicated in transcriptional regulation. This is the first report of JARID1A as a partner gene in leukemia. 2006 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16419055     DOI: 10.1002/gcc.20308

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  47 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  Molecular mechanisms and potential functions of histone demethylases.

Authors:  Susanne Marije Kooistra; Kristian Helin
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

3.  NRIP3: a novel translocation partner of MLL detected in a pediatric acute myeloid leukemia with complex chromosome 11 rearrangements.

Authors:  Brian V Balgobind; C Michel Zwaan; Claus Meyer; Rolf Marschalek; Rob Pieters; H Berna Beverloo; Marry M Van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

Review 4.  Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease.

Authors:  Paul A C Cloos; Jesper Christensen; Karl Agger; Kristian Helin
Journal:  Genes Dev       Date:  2008-05-01       Impact factor: 11.361

5.  Selective targeting of histone methylation.

Authors:  Abul B M M K Islam; William F Richter; Nuria Lopez-Bigas; Elizaveta V Benevolenskaya
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

Review 6.  Histone methylation: a dynamic mark in health, disease and inheritance.

Authors:  Eric L Greer; Yang Shi
Journal:  Nat Rev Genet       Date:  2012-04-03       Impact factor: 53.242

Review 7.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

8.  Functional analysis of the NUP98-CCDC28A fusion protein.

Authors:  Arnaud Petit; Christine Ragu; Gwendoline Soler; Chris Ottolenghi; Caroline Schluth; Isabelle Radford-Weiss; Sylvie Schneider-Maunoury; Isabelle Callebaut; Nicole Dastugue; Harry A Drabkin; Olivier A Bernard; Serge Romana; Virginie Penard-Lacronique
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 9.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

Review 10.  Histone lysine demethylases as targets for anticancer therapy.

Authors:  Jonas W Højfeldt; Karl Agger; Kristian Helin
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.